สำนักงานราชบัณฑิตยสภา

101 ใจนุช จงรั กษ์ วารสารราชบัณฑิตยสถาน ปีที่ ๓๘ ฉบับที่ ๓ ก.ค.-ก.ย. ๒๕๕๖ Licata AA. Discovery, clinical development and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39: 668-77. Martin TJ, Grin V. Bisphosphonates-mechanism of action. Australian prescriber 2000: 23; 130-132. Marx RE, Fotin M and Broumand V. Bisphosphonate-induced exposed bone [osteonecrosis/osteopetrosis] of the Jaws: risk factors, recognition, prevention and treatment. American Assoc of Oral Maxillofac Surg 2005; 63: 1567-75. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone [osteonecrosis/osteopetrosis] of the jaws: Risk factor, recognition, prevention, and treatment. J Oral Maxillofac Sur. 2005, 63: 1567-75. Marx RE, Cillo JE Jr, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: Risk factor, prediction of risk using serumCTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007: 65; 2397. Marx RE, Johnson RP. Studies in the radiobiology osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol, 1987; 64: 379-90. Marx RE. Pamidronate [Aredia] and Zoledronate [Zometa] induced avascular necrosis of the jaws; a growing epidemic. J Oral Maxillofac Surg 2003: 61: 1115-7. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate associated osteonecrosis. An American Academy of Oral Medicine position paper. 2005:136: 1658-1668. Migliorati CA. Bisphosphonate and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21 4253-4. Miles AE. Phosphorus necrosis of the jaw: “phossy jaw”. Br Dent J 1972: 133; 203-6. Milillo P, Garribba AP, Favia G, Ettorre GC. Jaw osteonecrosis in patients treat with bisphosphonate; MDCT evaluation 2007. Radiol Med Torino 112: 603-11.